Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

Background:Tumour-infiltrating lymphocytes (TILs) are known to be associated with response to primary systemic therapy (PST) in breast cancer. This study was conducted to assess the association of TIL subsets with pathological complete response (pCR) after PST in breast cancer in relation to breast cancer subtype, breast cancer stem cell (BCSC) phenotype and epithelial–mesenchymal transition (EMT).Methods:The pre-chemotherapeutic biopsy specimens of 153 breast cancer patients who underwent surgical resection after anthracycline- or anthracycline/taxane-based PST were analysed. TIL subsets (CD4+, CD8+, and FOXP3+ TILs), BCSC phenotype, and the expression of EMT markers were evaluated by immunohistochemistry and were correlated with pCR after PST.Results:Infiltration of CD4+ and CD8+ T lymphocytes was closely correlated with BCSC phenotype and EMT. High levels of CD4+, CD8+, and FOXP3+ TILs were associated with pCR, and CD8+ TILs were found to be an independent predictive factor for pCR. In addition, CD8+ TILs were associated with pCR irrespective of breast cancer subtype, CD44+/CD24− phenotype, EMT, and chemotherapeutic regimen in subgroup analyses.Conclusion:These findings indicate that CD8+ cytotoxic T lymphocytes are a key component of TILs associated with chemo-response and can be used as a reliable predictor of response to anthracycline- or anthracycline/taxane-based PST in breast cancer.

• Publication year

  2013

• Venue

  British Journal of Cancer

• Publication date

  2013-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.2013.634PMID 24129232PMCID 3833219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

  2013cited by this paper
• Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

  2013cited by this paper
• Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects

  2012cited by this paper
• Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis

  2012cited by this paper
• Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

  2012cited by this paper
• CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

  2012cited by this paper
• Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients

  2012cited by this paper
• Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

  2012cited by this paper
• Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

  2011cited by this paper
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• Stimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer

  2011cited by this paper
• Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

  2011cited by this paper
• Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

  2011cited by this paper
• Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.

  2011influential reference
• Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells.

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

  2010cited by this paper
• EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

  2010cited by this paper
• Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy

  2010cited by this paper
• Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer

  2010cited by this paper
• Paclitaxel and immune system.

  2009cited by this paper
• Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

  2009cited by this paper
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

  2009cited by this paper
• Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

  2009cited by this paper
• In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

  2009cited by this paper
• Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

  2008cited by this paper
• The humoral immune system has a key prognostic impact in node-negative breast cancer.

  2008cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

  2008cited by this paper
• Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma

  2008cited by this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cited by this paper
• Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6‘split apart’ probes

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

  2008cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Immune surveillance of tumors.

  2007cited by this paper
• Triple negative tumours: a critical review

  2007cited by this paper
• Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression

  2007cited by this paper
• Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition1

  2006influential reference
• Significantly Higher Pathologic Complete Remission Rate after Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

  2005cited by this paper
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

  2005cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment

  2004cited by this paper
• The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

  2002influential reference
• Lymphocyte infiltrates as a prognostic variable in female breast cancer.

  1992cited by this paper

• The peripheral blood lymphocyte signatures forecast therapeutic efficacy in papillary thyroid cancer patients undergoing radioactive iodine therapy

  2026cites this paper
• Supervised machine learning to quantitatively assess the prognostic value of tumor-infiltrating lymphocytes in gastric cancer

  2026cites this paper
• Prognostic relevance of specific TIL (CD4+, CD8+, and FOXP3 + T-cell infiltrates) in triple-negative breast cancer: short- and long-term outcomes

  2026cites this paper
• FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer.

  2026cites this paper
• A computer vision method to evaluate tumor-infiltrating lymphocytes and multiparametric modeling of neoadjuvant systemic therapy response in breast cancer.

  2026cites this paper
• Interaction between the breast tumor microenvironment and gut microbiome

  2025cites this paper
• The global trends and distribution in tumor-infiltrating lymphocytes over the past 49 years: bibliometric and visualized analysis

  2025cites this paper
• Roles of Tumor-Infiltrating Lymphocytes and Antitumor Immune Responses as Predictive and Prognostic Markers in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy

  2025influential citation
• Anti-Breast Cancer Effects of Thymoquinone-Chemotherapeutic Combinations: A Systematic Review of the Latest In Vitro and In Vivo Studies

  2025cites this paper
• The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer.

  2025cites this paper
• The interplay between the immune response and neoadjuvant therapy in breast cancer

  2025cites this paper
• Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis

  2025cites this paper
• Virtual multiplex immunofluorescence identifies lymphocyte subsets predictive of response to neoadjuvant therapy

  2025cites this paper
• Distinct profiles of osteoclast and dendritic cell-mediated expansion and functional activation of NK and T cells

  2025cites this paper
• Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy

  2025cites this paper
• Immunoscore CD3/CD8 and FOXP3 Expression Correlate to Neoadjuvant Chemotherapy Response in Triple Negative Breast Cancer: A Case-Control Study

  2025cites this paper
• Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

  2025cites this paper
• The role of peripheral T lymphocyte subsets and PD-1 expression as a biomarker for neoadjuvant treatment response in breast cancer.

  2025cites this paper
• Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44hi/CD24lo-ALDH1hi as an Independent Prognostic Factor After Neoadjuvant Chemotherapy

  2025cites this paper
• Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy

  2025cites this paper
• Thematic trends and knowledge-map of tumor-infiltrating lymphocytes in breast cancer: a scientometric analysis

  2024cites this paper
• Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors

  2024cites this paper
• Mechanisms of drug resistance to neoadjuvant chemotherapy in breast cancer

  2024cites this paper
• Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?

  2024cites this paper
• Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package

  2024cites this paper
• To Assess the Predictive and Prognostic Role of PD-L1 and CD8 Following Neoadjuvant Chemotherapy in Breast Cancer

  2024cites this paper
• The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer

  2024cites this paper
• Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer

  2024cites this paper
• Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment

  2024cites this paper
• Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer

  2024cites this paper
• Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy

  2024cites this paper
• Intra‐tumoral tumor infiltrating Lymphocyte‐T CD8+ and chemotherapy response in colorectal cancer: A prospective observational study

  2024cites this paper
• CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

  2024influential citation
• Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer

  2024cites this paper
• Detailed Profiling of the Tumor Microenvironment in Ethnic Breast Cancer, Using Tissue Microarrays and Multiplex Immunofluorescence

  2024cites this paper
• Interferon-Gamma Secretion Is Significantly Decreased in Stage III Breast Cancer Patients

  2024cites this paper
• Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.

  2024cites this paper
• Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-14

  2024cites this paper
• A practical approach to febrile cancer patients: Diagnostic stewardship in Oncology units

  2024cites this paper
• Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management

  2023cites this paper
• HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment

  2023cites this paper
• Early changes of platelet‑lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer

  2023cites this paper
• Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

  2023cites this paper
• The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy

  2023cites this paper
• The Peritumoral CD8+/FOXP3+ Cell Ratio Has Prognostic Value in Triple-negative Breast Cancer

  2023cites this paper
• The circRNA-0001361/miR-491/FGFR4 axis is associated with axillary response evaluated by ultrasound following NAC in subjects with breast cancer

  2023cites this paper
• The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort.

  2023cites this paper
• Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images

  2023cites this paper
• Prognostic value of CD4+ in patients with Т1–2N0M0 breast cancer

  2023cites this paper
• Prognostic and predictive value of a novel 100-point scale in patients with T1–2N0M0 breast cancer

  2023cites this paper
• signifinder enables the identification of tumor cell states and cancer expression signatures in bulk, single-cell and spatial transcriptomic data

  2023cites this paper
• Metastasis of breast cancer to bones alters the tumor immune microenvironment

  2023cites this paper
• Explainable Machine Learning Reveals the Role of the Breast Tumor Microenvironment in Neoadjuvant Chemotherapy Outcome

  2023cites this paper
• Regulation of Cytotoxic Immune Effector Function by AJ3 Probiotic Bacteria in Amyotrophic Lateral Sclerosis (ALS).

  2023cites this paper
• CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs

  2023cites this paper
• The prognostic values of FOXP3^+ tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis

  2023cites this paper
• HSF1 excludes CD8+ T cells from breast tumors via suppression of CCL5

  2023cites this paper
• The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study

  2023cites this paper
• Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment

  2023cites this paper
• Total and Intratumoral CD8+ T Cell Expressions are Correlated with Miller Payne Grading and WHO Clinical Response of Neoadjuvant Chemotherapy

  2023influential citation
• Analysis of lymphocytic infiltrate as a predictive factor of neck metastases in oral squamous cell carcinoma

  2023cites this paper
• Systematic Multiomic Analysis of PKHD1L1 Gene Expression and Its Role as a Predicting Biomarker for Immune Cell Infiltration in Skin Cutaneous Melanoma and Lung Adenocarcinoma

  2023cites this paper
• Cancer stem cell–immune cell crosstalk in breast tumor microenvironment: a determinant of therapeutic facet

  2023cites this paper
• Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis

  2023cites this paper
• Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and survival in undifferentiated pleomorphic sarcoma (NLR, PLR, and overall survival in UPS).

  2023cites this paper
• Association of WHSC1/NSD2 and T-cell infiltration with prostate cancer metastasis and prognosis

  2023cites this paper
• Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer

  2022cites this paper
• Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.

  2022cites this paper
• Cancer Stem Cells: An Ever-Hiding Foe.

  2022cites this paper
• Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study

  2022cites this paper
• Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC

  2022cites this paper
• Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker

  2022cites this paper
• The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats

  2022cites this paper
• Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer

  2022cites this paper
• Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand

  2022cites this paper
• Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors

  2022cites this paper
• Expression of PD-L1 in Locally Advanced Breast Cancer and Its Impact on Neoadjuvant Chemotherapy Response

  2022cites this paper
• Can granulysin provide prognostic value in primary breast cancer?

  2022cites this paper
• Immuno-genomic profiling of biopsy specimens predicts neoadjuvant chemotherapy response in esophageal squamous cell carcinoma

  2022cites this paper
• Body Microbiota and Its Relationship With Benign and Malignant Breast Tumors: A Systematic Review

  2022cites this paper
• Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients

  2022cites this paper
• The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer

  2022cites this paper
• Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

  2022cites this paper
• The Immune Microenvironment in Gastric Cancer: Prognostic Prediction

  2022cites this paper
• Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression

  2022cites this paper
• Identifying glycolysis-related LncRNAs for predicting prognosis in breast cancer patients

  2022cites this paper
• Preclinical development of ZED8, an ^89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

  2022cites this paper
• Phenotypic Heterogeneity of Triple-Negative Breast Cancer Mediated by Epithelial–Mesenchymal Plasticity

  2021cites this paper
• Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors.

  2021cites this paper
• Next-Generation Digital Histopathology of the Tumor Microenvironment

  2021cites this paper
• M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma

  2021cites this paper
• The Immunology of Hormone Receptor Positive Breast Cancer

  2021cites this paper
• Immunological Role and Prognostic Value of APBB1IP in Pan-Cancer Analysis

  2021cites this paper
• Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications

  2021cites this paper
• Accuracy of a Novel Scoring System for Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

  2021cites this paper
• Study on Treatment and Prognostic Markers of Triple-Negative Breast Cancer

  2021cites this paper
• Intratumoural Effector Cell Subpopulations in Breast Cancer: a Literature Review and Own Data Report

  2021cites this paper
• Significance of (IMP3) In Dysplasia- Adenocarcinoma Sequence in Barrett's Esophagus. (Immunohistochemical Study)

  2021cites this paper
• Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy

  2021cites this paper
• Predicting the Level of Tumor-Infiltrating Lymphocytes in Patients With Breast Cancer: Usefulness of Mammographic Radiomics Features

  2021cites this paper